Skip to main content
Top
Published in: International Urology and Nephrology 3/2011

01-09-2011 | Urology – Original Paper

Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury

Authors: Guoqing Chen, Limin Liao

Published in: International Urology and Nephrology | Issue 3/2011

Login to get access

Abstract

Background

To present a comprehensive experience of botulinum toxin A (BTX-A) injected into the detrusor muscle in patients with spinal cord injuries (SCI) causing neurogenic detrusor overactivity.

Methods

Three hundred units of BTX-A were injected cystoscopically into the detrusor muscle of 108 patients with neurogenic detrusor overactivity secondary to SCI at 30 different locations. Evaluations were performed before the injections and 6 weeks after, and they included determination of bladder urinary continence status, frequency/volume chart of CIC, concomitant anticholinergic medication use, Incontinence Quality of Life questionnaire (I-QOL) and patient satisfaction. Key urodynamic parameters (reflex volume, maximum detrusor pressure during voiding, detrusor compliance and maximum cystometric capacity) were analyzed at the outset and during the follow-up (6, 12 and 36 weeks) examinations.

Results

By the time of the urodynamic follow-up examinations (6, 12 and 36 weeks), the mean cystometric capacity (P < 0.05) and the mean reflex volume (P < 0.05) increased significantly, while the mean voiding pressure (P < 0.05) decreased significantly. No complications or side effects were reported. Most patients considerably reduced or even stopped taking anticholinergic drugs and were satisfied with the treatment.

Conclusions

This retrospective study indicates that BTX-A injections into the detrusor muscle to treat neurogenic detrusor overactivity secondary to SCI are safe and valuable. Significant improvement of bladder function corresponded with continence and subjective satisfaction indicated by the treated patients.
Literature
1.
go back to reference Sekhon LH, Fehlings MG (2001) Epidemiology,demographics, and pathophysiology of acute spinal cord injury. Spine 26(24 Suppl):S2–S12PubMedCrossRef Sekhon LH, Fehlings MG (2001) Epidemiology,demographics, and pathophysiology of acute spinal cord injury. Spine 26(24 Suppl):S2–S12PubMedCrossRef
2.
go back to reference Riccabona M, Koen M, Schindler M et al (2004) Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:845–848PubMedCrossRef Riccabona M, Koen M, Schindler M et al (2004) Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:845–848PubMedCrossRef
3.
go back to reference Schurch B, Stohrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697PubMedCrossRef Schurch B, Stohrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697PubMedCrossRef
4.
go back to reference Lacy DB, Tepp W, Cohen AC et al (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898–902PubMedCrossRef Lacy DB, Tepp W, Cohen AC et al (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898–902PubMedCrossRef
5.
go back to reference de Paiva A, Meunier FA, Molgo J et al (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:3200–3205PubMedCrossRef de Paiva A, Meunier FA, Molgo J et al (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:3200–3205PubMedCrossRef
6.
go back to reference Stohrer M, Schurch B, Kramer G et al (1999) Botulinum A toxin in the treatment of detrusor hyperreflexia in spinal cord injury. A new alternative to medical and surgical procedures? Neurourol Urodyn 18:401–402CrossRef Stohrer M, Schurch B, Kramer G et al (1999) Botulinum A toxin in the treatment of detrusor hyperreflexia in spinal cord injury. A new alternative to medical and surgical procedures? Neurourol Urodyn 18:401–402CrossRef
7.
go back to reference Rieder CR, Schestatsky P, Socal MP et al (2007) A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 30:39–42PubMedCrossRef Rieder CR, Schestatsky P, Socal MP et al (2007) A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 30:39–42PubMedCrossRef
8.
go back to reference Quagliato EM, Carelli EF, Viana MA (2010) Prospective, randomized, double-blind study, comparing botulinum toxins type A botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol 33:27–31PubMed Quagliato EM, Carelli EF, Viana MA (2010) Prospective, randomized, double-blind study, comparing botulinum toxins type A botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol 33:27–31PubMed
9.
go back to reference Maynard FM Jr, Bracken MB, Creasey G et al (1997) International standards for neurological and functional classification of spinal cord injury. American spinal injury association. Spinal Cord 35:266–274PubMedCrossRef Maynard FM Jr, Bracken MB, Creasey G et al (1997) International standards for neurological and functional classification of spinal cord injury. American spinal injury association. Spinal Cord 35:266–274PubMedCrossRef
10.
go back to reference Blaivas JG, Awad SA, Bissada N et al (2005) Urodynamic procedures: recommendations of the urodynamic society I. Procedures that should be available for routine urologic practice. Neurourol Urodyn 1:51–55CrossRef Blaivas JG, Awad SA, Bissada N et al (2005) Urodynamic procedures: recommendations of the urodynamic society I. Procedures that should be available for routine urologic practice. Neurourol Urodyn 1:51–55CrossRef
11.
go back to reference Schurch B, Denys P, Kozma CM et al (2007) Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 52:850–858PubMedCrossRef Schurch B, Denys P, Kozma CM et al (2007) Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 52:850–858PubMedCrossRef
12.
go back to reference Schulte-Baukloh H, Weiss C, Stolze T et al (2005) Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48:984–990PubMedCrossRef Schulte-Baukloh H, Weiss C, Stolze T et al (2005) Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48:984–990PubMedCrossRef
13.
go back to reference Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515PubMedCrossRef Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515PubMedCrossRef
14.
go back to reference Smith CP, Gangitano DA, Munoz A et al (2008) Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 52:1068–1075PubMedCrossRef Smith CP, Gangitano DA, Munoz A et al (2008) Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 52:1068–1075PubMedCrossRef
15.
go back to reference Dixon J, Glosing J (1987) Structure and innervation in the human. In: Torrens M, Morrison JFB (eds) The physiology of the lower urinary tract. Springer, New York, pp 3–22 Dixon J, Glosing J (1987) Structure and innervation in the human. In: Torrens M, Morrison JFB (eds) The physiology of the lower urinary tract. Springer, New York, pp 3–22
16.
go back to reference Brading A (1987) Physiology of bladder smooth muscle. In: Torrens M, Morrison JFB (eds) The physiology of the lower urinary tract. Springer, New York, pp 161–192 Brading A (1987) Physiology of bladder smooth muscle. In: Torrens M, Morrison JFB (eds) The physiology of the lower urinary tract. Springer, New York, pp 161–192
17.
go back to reference Akbar M, Abel R, Seyler TM et al (2007) Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 100:639–645PubMedCrossRef Akbar M, Abel R, Seyler TM et al (2007) Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 100:639–645PubMedCrossRef
18.
go back to reference Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868–872PubMedCrossRef Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868–872PubMedCrossRef
19.
go back to reference Kuo HC (2005) Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66:94–98PubMedCrossRef Kuo HC (2005) Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66:94–98PubMedCrossRef
20.
go back to reference Schurch B, Denys P, Kozma CM et al (2007) Reliability and validity of the incontinence quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 88:646–652PubMedCrossRef Schurch B, Denys P, Kozma CM et al (2007) Reliability and validity of the incontinence quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 88:646–652PubMedCrossRef
21.
go back to reference Hori S, Patki P, Attar KH (2009) Patients’ perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. BJU Int 104:216–220PubMedCrossRef Hori S, Patki P, Attar KH (2009) Patients’ perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. BJU Int 104:216–220PubMedCrossRef
22.
go back to reference Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659PubMedCrossRef Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659PubMedCrossRef
23.
go back to reference Schulte-Baukloh H, Knispel HH, Stolze T et al (2005) Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 66:865–870PubMedCrossRef Schulte-Baukloh H, Knispel HH, Stolze T et al (2005) Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 66:865–870PubMedCrossRef
24.
go back to reference Dressler D, Hallett M (2006) Immunological aspects of botox, dysport and myobloc/neurobloc. Eur J Neurol 13(Suppl. 1):11–15PubMedCrossRef Dressler D, Hallett M (2006) Immunological aspects of botox, dysport and myobloc/neurobloc. Eur J Neurol 13(Suppl. 1):11–15PubMedCrossRef
25.
go back to reference Herrmann J, Geth K, Mall V et al (2004) Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55:732–735PubMedCrossRef Herrmann J, Geth K, Mall V et al (2004) Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55:732–735PubMedCrossRef
Metadata
Title
Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury
Authors
Guoqing Chen
Limin Liao
Publication date
01-09-2011
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2011
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9873-x

Other articles of this Issue 3/2011

International Urology and Nephrology 3/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.